BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 28061437)

  • 21. Methylation Density Pattern of
    Fabrizio FP; Sparaneo A; Centra F; Trombetta D; Storlazzi CT; Graziano P; Maiello E; Fazio VM; Muscarella LA
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31159323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Demethylation of miR-10b plays a suppressive role in ccRCC cells.
    He C; Zhao X; Jiang H; Zhong Z; Xu R
    Int J Clin Exp Pathol; 2015; 8(9):10595-604. PubMed ID: 26617769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating KEAP1/Nrf2 signaling pathway.
    Huang H; Zhang J; Jiang P; Xu X; Huang F; Zhao B; Wang X; Zhou L
    Anticancer Drugs; 2023 Feb; 34(2):248-256. PubMed ID: 36730618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
    Cooper SJ; Zou H; Legrand SN; Marlow LA; von Roemeling CA; Radisky DC; Wu KJ; Hempel N; Margulis V; Tun HW; Blobe GC; Wood CG; Copland JA
    Oncogene; 2010 May; 29(20):2905-15. PubMed ID: 20208565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
    Mitsui Y; Hirata H; Arichi N; Hiraki M; Yasumoto H; Chang I; Fukuhara S; Yamamura S; Shahryari V; Deng G; Saini S; Majid S; Dahiya R; Tanaka Y; Shiina H
    Oncotarget; 2015 Apr; 6(11):9577-91. PubMed ID: 25797254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma.
    Lv D; Zhao W; Dong D; Qian XP; Zhang Y; Tian XJ; Zhang J
    Eur J Cancer; 2011 Sep; 47(13):2068-76. PubMed ID: 21600761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylation of the KEAP1 gene promoter region in human colorectal cancer.
    Hanada N; Takahata T; Zhou Q; Ye X; Sun R; Itoh J; Ishiguro A; Kijima H; Mimura J; Itoh K; Fukuda S; Saijo Y
    BMC Cancer; 2012 Feb; 12():66. PubMed ID: 22325485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.
    Wang X; Cheng Y; Zhu Y; Li H; Ge W; Wu X; Zhao K; Yuan J; Li Z; Jiang S; Han Z; Jiang Q; Wu Q; Liu T; Zhang C; Yu M; Hu Y
    Int J Cancer; 2017 Oct; 141(7):1422-1433. PubMed ID: 28656647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human age‑related cataracts: epigenetic suppression of the nuclear factor erythroid 2‑related factor 2‑mediated antioxidant system.
    Gao Y; Yan Y; Huang T
    Mol Med Rep; 2015 Feb; 11(2):1442-7. PubMed ID: 25370996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acetyl-l-carnitine prevents homocysteine-induced suppression of Nrf2/Keap1 mediated antioxidation in human lens epithelial cells.
    Yang SP; Yang XZ; Cao GP
    Mol Med Rep; 2015 Jul; 12(1):1145-50. PubMed ID: 25776802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KEAP1/NRF2 signaling pathway mutations in cervical cancer.
    Chu XY; Li ZJ; Zheng ZW; Tao YL; Zou FX; Yang XF
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4458-4466. PubMed ID: 30058679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2-Keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma.
    Danilovic DLS; de Mello ES; Frazzato EST; Wakamatsu A; de Lima Jorge AA; Hoff AO; Marui S
    Head Neck; 2018 Jun; 40(6):1271-1278. PubMed ID: 29469959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
    Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OSR1 is a novel epigenetic silenced tumor suppressor regulating invasion and proliferation in renal cell carcinoma.
    Zhang Y; Yuan Y; Liang P; Guo X; Ying Y; Shu XS; Gao M; Cheng Y
    Oncotarget; 2017 May; 8(18):30008-30018. PubMed ID: 28404905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic regulation of microRNA expression in renal cell carcinoma.
    Schiffgen M; Schmidt DH; von Rücker A; Müller SC; Ellinger J
    Biochem Biophys Res Commun; 2013 Jun; 436(1):79-84. PubMed ID: 23707942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulating Nrf2-dependent antioxidant defenses in Pacific oysters Crassostrea gigas: Investigating the Nrf2/Keap1 pathway in bivalves.
    Danielli NM; Trevisan R; Mello DF; Fischer K; Deconto VS; da Silva Acosta D; Bianchini A; Bainy AC; Dafre AL
    Comp Biochem Physiol C Toxicol Pharmacol; 2017 May; 195():16-26. PubMed ID: 28216009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
    Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
    Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.